AJ PHARMA Group has successfully completed its first global vaccine business acquisition in Denmark.
The 100% acquisition creates an independent vaccines production business from the Danish Government-owned Statens Serum Institut (SSI).
Renamed AJ Vaccines, this new entity is already an established and internationally recognised vaccine manufacturer that produces strategic vaccines such as inactivated polio vaccine (IPV), BCG, and others that are critical for public health, and will significantly contribute towards achieving national vaccine self-reliance in Malaysia.
The completion of this acquisition is a significant milestone in the AJ Pharma Group’s global strategy to create a stronger presence in the vaccine market across the world.
More significantly, AJ Vaccines complements the group’s ongoing project to establish a vaccine formulation, fill and finish facility in Malaysia through AJ Biologics Sdn Bhd.
AJ Vaccines chairman Dr Tabassum Khan said, “With this acquisition of AJ Vaccines in Denmark, we are now one step closer to achieving our vision of becoming a top vaccines player in the world. We are now in a prime position to achieve economic, social and humanitarian objectives, for Malaysia and beyond.
“AJ Vaccines opens new avenues for strengthening growth of the vaccines industry and achieving national vaccine self-reliance in Malaysia. We acknowledge and value the continued encouragement and support of the Malaysian Government in realising our goals.
“The wider production portfolio of AJ Vaccines is synergistic to the Group’s purpose of bringing a balanced paediatric and adult vaccine range to meet the public health needs of Malaysia along with targeted regional and global markets.
“In line with national objectives under the purview of the Healthcare ETP and Vision 2020 of the National Biotechnology Policy, this acquisition will also see technology transfer and human capital development from the Danish facility into Malaysia,” he added.
The Danish acquisition will enable the AJ Pharma Group to leverage the established vaccine portfolio and manufacturing expertise that SSI has built over the years. SSI’s public health image and legacy across many countries will also benefit the group largely.
With a committed investment of US$45mil (RM200.23mil), the AJ Biologics facility located in Bandar Enstek is on track to be operational by the fourth quarter of 2018. This project has also been awarded BioNexus status and is recognised as an entry-point-project under the National Key Economic Area (NKEA).
AJ Vaccine’s business has also been widely recognised for its contribution in research and production of vaccines for infectious diseases and biological threats. The strategic acquisition sees the two parties jointly collaborating to plan, transfer knowledge and manage expertise in developing the vaccines industry in Malaysia and worldwide.